论文部分内容阅读
目的:观察双倍剂量的福辛普利钠(血管紧张素转化酶抑制剂)治疗非IgA系膜增生性肾小球肾炎的疗效。方法:40例经病理确诊为非IgA系膜增生性肾小球肾炎的患者随机分为治疗组和对照组各20例,治疗组予双倍剂量福辛普利钠(20mg/天)口服治疗6个月,对照组予单倍剂量福辛普利钠(10mg/天)口服治疗6月,分别于治疗前、治疗后3月、6月测定患者的24小时尿蛋白定量、血清白蛋白、肌酐。结论:应用双倍剂量福辛普利钠能明显减少尿蛋白、保护肾功能,疗效优于单倍剂量的福辛普利钠。
Objective: To observe the effect of double dose of fosinopril sodium (angiotensin converting enzyme inhibitor) on non-IgA mesangial proliferative glomerulonephritis. Methods: Forty patients with pathologically diagnosed non-IgA mesangial proliferative glomerulonephritis were randomly divided into treatment group (20 cases) and control group (20 cases). Patients in treatment group were treated with double dose of fosinopril sodium (20 mg / day) Six months later, the control group was treated with single-dose fosinopril sodium (10mg / day) orally for 6 months. The 24-hour urinary protein, serum albumin, Creatinine. Conclusion: Double dose of fosinopril sodium can significantly reduce urinary protein, protect renal function, the effect is better than single dose of fosinopril sodium.